Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.05)
# 3,067
Out of 4,996 analysts
112
Total ratings
37%
Success rate
-4.38%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLNN Clene | Maintains: Buy | $83 → $48 | $5.81 | +726.16% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $5.80 | +158.62% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $8.28 | +226.09% | 6 | Jul 29, 2025 | |
| ATAI Atai Life Sciences | Maintains: Buy | $12 → $11 | $5.27 | +108.73% | 3 | Jul 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $5.86 | +1,094.54% | 8 | Jul 8, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $1.97 | +762.94% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $142.00 | +12.68% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $137.37 | +60.15% | 21 | May 2, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $9.77 | +155.89% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $4.52 | +165.49% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $2.70 | +2,862.96% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $14.44 | +93.91% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $10.67 | +31.21% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $24.14 | -17.15% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $21.05 | +56.77% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $15.00 | +900.00% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $18.34 | - | 2 | Jan 31, 2017 |
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $5.81
Upside: +726.16%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $5.80
Upside: +158.62%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $8.28
Upside: +226.09%
Atai Life Sciences
Jul 28, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $5.27
Upside: +108.73%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $5.86
Upside: +1,094.54%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $1.97
Upside: +762.94%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $142.00
Upside: +12.68%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $137.37
Upside: +60.15%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $9.77
Upside: +155.89%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.52
Upside: +165.49%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.70
Upside: +2,862.96%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $14.44
Upside: +93.91%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $10.67
Upside: +31.21%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $24.14
Upside: -17.15%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $21.05
Upside: +56.77%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $15.00
Upside: +900.00%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $18.34
Upside: -